These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 35462426)

  • 1. Complete blood collection-based systemic inflammation biomarkers for patients with hidradenitis suppurativa.
    Gambichler T; Hessam S; Cramer P; Abu Rached N; Bechara FG
    J Eur Acad Dermatol Venereol; 2022 Sep; 36(9):1593-1596. PubMed ID: 35462426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of new inflammatory markers in determining disease activation and severity in patients with hidradenitis suppurativa.
    Öksüm Solak E; Baran Ketencioglu B; Cinar SL; Kartal D; Borlu M
    Int J Dermatol; 2023 Aug; 62(8):1076-1081. PubMed ID: 37306156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarkers of systemic inflammation are associated with disease severity and metabolic syndrome in patients with hidradenitis suppurativa.
    Holgersen N; Nielsen VW; Rosenø NAL; Thyssen JP; Egeberg A; Nielsen SH; Ring HC; Thomsen SF
    JAAD Int; 2024 Jun; 15():170-178. PubMed ID: 38638915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between inflammatory markers over time and disease severity in status epilepticus: a preliminary study.
    Shi X; Zhang X; Song S; Pan H; Huang C; Sun T; Wang S; Xu J
    Front Neurol; 2024; 15():1334415. PubMed ID: 38370523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of systemic immune and inflammatory biomarkers in hidradenitis suppurativa.
    Utlu Z
    Eur Rev Med Pharmacol Sci; 2023 Oct; 27(19):9267-9272. PubMed ID: 37843340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring the role of systemic immune-inflammation index and neutrophil-lymphocyte ratio in cardiovascular risk stratification for patients with hidradenitis suppurativa: A cross-sectional study.
    Sánchez-Díaz M; Salvador-Rodríguez L; Cuenca-Barrales C; Arias-Santiago S; Molina-Leyva A
    J Dermatol; 2022 Dec; 49(12):1238-1244. PubMed ID: 36000267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the laboratory parameters in hidradenitis suppurativa: Can we use new inflammatory biomarkers?
    Çetinarslan T; Türel Ermertcan A; Özyurt B; Gündüz K
    Dermatol Ther; 2021 Mar; 34(2):e14835. PubMed ID: 33527638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Haptoglobin is an independent marker for disease severity and risk for metabolic complications in hidradenitis suppurativa: A prospective study.
    Abu Rached N; Gambichler T; Ocker L; Skrygan M; Seifert C; Scheel CH; Stockfleth E; Bechara FG
    J Eur Acad Dermatol Venereol; 2024 Jan; 38(1):205-213. PubMed ID: 37669834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anemia and Systemic Inflammatory Markers in Patients with Perianal Disease: Hidradenitis Suppurativa and Inflammatory Bowel Disease.
    Yamanaka-Takaichi M; Raffals LE; Ehman EC; Loftus EV; Alavi A
    Dermatology; 2023; 239(5):843-848. PubMed ID: 37356426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COMPLETE BLOOD COUNT DERIVED INFLAMMATORY BIOMARKERS IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES.
    Nanava N; Betaneli M; Giorgobiani G; Chikovani T; Janikashvili N
    Georgian Med News; 2020 May; (302):39-44. PubMed ID: 32672687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of hematological inflammatory parameters in patients with palmoplantar pustulosis.
    Ning X; Wu C; Song B; Wang HM; Jin HZ
    Int J Dermatol; 2024 May; ():. PubMed ID: 38736134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two Cases of Hidradenitis Suppurativa Treated with Adalimumab at the Department of Dermatology and Venereology, Clinical Hospital Mostar.
    Lovrić I; Brkić J; Ćorluka M; Čović M; Pejić J; Zeljko Penavić J
    Acta Dermatovenerol Croat; 2021 Jul; 29(2):108-110. PubMed ID: 34477078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of inflammatory serum markers with disease severity in patients with hidradenitis suppurativa (HS).
    Hessam S; Sand M; Gambichler T; Bechara FG
    J Am Acad Dermatol; 2015 Dec; 73(6):998-1005. PubMed ID: 26410359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. INFLAMMATORY BIOMARKERS IN PATIENTS WITH UNRESECTABLE PANCREATIC CANCER: A RETROSPECTIVE STUDY.
    Toria N; Kikodze N; Rukhadze R; Mizandari M; Chikovani T
    Georgian Med News; 2020 Feb; (299):21-26. PubMed ID: 32242838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio levels are associated with keratoconus.
    Elbeyli A; Kurtul BE
    Indian J Ophthalmol; 2021 Jul; 69(7):1725-1729. PubMed ID: 34146015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patients with hidradenitis suppurativa carry a higher systemic inflammatory load than other dermatological patients.
    Riis PT; Søeby K; Saunte DM; Jemec GB
    Arch Dermatol Res; 2015 Dec; 307(10):885-9. PubMed ID: 26350517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive value of the neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, platelet-to-neutrophil ratio, and neutrophil-to-monocyte ratio in lupus nephritis.
    Liu P; Li P; Peng Z; Xiang Y; Xia C; Wu J; Yang B; He Z
    Lupus; 2020 Aug; 29(9):1031-1039. PubMed ID: 32501169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum Inflammatory Biomarkers in Patients with Nonarteritic Anterior Ischemic Optic Neuropathy.
    Koçak N; Eraydın B; Turunç M; Yeter V; Güngör İ
    Korean J Ophthalmol; 2020 Dec; 34(6):478-484. PubMed ID: 33307608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in evaluation of inflammation in non-dialysis patients with end-stage renal disease (ESRD).
    Li P; Xia C; Liu P; Peng Z; Huang H; Wu J; He Z
    BMC Nephrol; 2020 Nov; 21(1):511. PubMed ID: 33238906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
    Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
    J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.